• Philip Morris International (NYSE:PM) is accelerating its shift away from combustible cigarettes toward smoke free products.
• The company is highlighting rapid growth for its oral nicotine brand Zyn as a key part of this transition.
• PMI has expanded smoke free offerings into more than 100 markets as part of this push.
• The company has set an internal target for around two thirds of its revenue to come from smoke free products by 2030.

For you as an investor, this marks a meaningful phase for Philip Morris International, which has long been associated with traditional cigarettes. The company is emphasizing smoke free alternatives such as Zyn and other reduced risk nicotine products, in line with changing consumer preferences and tighter regulation around combustible tobacco in many markets.

The stated goal for roughly two thirds of revenue to come from smoke free products by 2030 indicates the extent of the shift in PMI’s business mix. This ambition, together with its presence in over 100 markets for smoke free offerings, provides a clearer sense of how the company is positioning itself within the broader tobacco and nicotine sector over the coming years.

Stay updated on the most important news stories for Philip Morris International by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Philip Morris International.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$187.50 vs a consensus target of US$194.09, the price sits about 3% below analyst expectations.
• ✅ Simply Wall St Valuation: Shares are described as trading 12.2% below estimated fair value, which points to a discount.
• ✅ Recent Momentum: A 30 day return of 4.82% shows the stock has had a positive short term run.

There is only one way to know the right time to buy, sell or hold Philip Morris International. Head to Simply Wall St's company report for the latest analysis of Philip Morris International's Fair Value.

Key Considerations

• 📊 The push toward smoke free products, including Zyn, makes this news most relevant if you care about how much of PMI's future mix comes from reduced risk nicotine.
• 📊 Keep an eye on the share of revenue from smoke free products versus the 2030 two thirds target, along with how pricing and volumes evolve around US$187.50 and the analyst target range of US$158 to US$210.
• ⚠️ Regulatory pressure on nicotine and tobacco remains a core risk, which matters as PMI scales Zyn and other smoke free offerings globally.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Philip Morris International analysis. Alternatively, you can check out the community page for Philip Morris International to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.